MAR 18, 2020 7:13 PM PDT

Drug Could Effectively Treat a Lethal Blood Cancer

WRITTEN BY: Nouran Amin

A pricey drug, called tyrosine kinase inhibitor (TKI), is used to continuously treat the blood cancer Chronic Myeloid Leukemia (CML).

The TKI treatment, if stopped, can cause the recurrence of CML. Even though most CML patients receive life-long TKI treatment—roughly 10 percent become resistant and progress to blast crisis (BC) CML. Once BC is reached, it is almost fatal and many factors that cause BC still remain unknown to clinicians.

"Our discovery is like finding the 'one ring that rules them all'. Since there are many cancer-causing genetic mutations that occur when chronic phase CML transforms to blast crisis, it has been very challenging to determine which ones are critical to BC, and therefore important to target. By discovering this 'one ring' and how to 'destroy' it with a novel drug combination, we open the door to treating this deadly cancer with the same combination of drugs regardless of the myriad mutations that exist in any particular patient. In addition, our study demonstrates the ability of scientists and clinicians to make exciting discoveries that can be translated to the improved health of patients all over the world, as well as Singaporeans," said Associate Professor Ong Sin Tiong from the Duke-NUS CSCB programme and corresponding author of this study.

Learn more about CML:

"As a haematologist treating patients with advanced blast crisis CML, it is disheartening when we run out of treatment options for them. And that is why we are very encouraged by the study findings and certainly hopeful that our patients may one day benefit from the efforts of our collaboration," Associate Professor Charles Chuah, Senior Consultant, Department of Haematology, SGH.

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
JAN 25, 2021
Cancer
Combining Radiotherapy and Immunotherapy in Liver Cancer
JAN 25, 2021
Combining Radiotherapy and Immunotherapy in Liver Cancer
The dream of a magic bullet drug plagues the mind of scientists, doctors, and patients. The truth is some diseases are j ...
JAN 10, 2021
Drug Discovery & Development
New Treatment for Botulism
JAN 10, 2021
New Treatment for Botulism
Researchers discover a new way to reverse botulism which can often lead to paralysis. Botulism is caused by the most pot ...
FEB 02, 2021
Genetics & Genomics
Using Genetic Tools to Find Treatment Options for PTSD
FEB 02, 2021
Using Genetic Tools to Find Treatment Options for PTSD
With genome-wide association studies, researchers have been able to link small variations in the genome to a greater (or ...
MAY 06, 2021
Cannabis Sciences
New CBD Analog Outperforms Regular CBD for Pain Relief
MAY 06, 2021
New CBD Analog Outperforms Regular CBD for Pain Relief
Researchers from Temple University Health System have found that a novel cannabidiol (CBD) analog can reverse pain sensi ...
MAY 11, 2021
Cardiology
Red Blood Cells Could Help Predict Recovery in Cardiovascular Patients
MAY 11, 2021
Red Blood Cells Could Help Predict Recovery in Cardiovascular Patients
Cells are one of the basic building blocks of life. There are hundreds of different cell types, and they all work togeth ...
Loading Comments...